Physician profile
Charles Luu
NPI 1306831649
$15,126.58
in general payments reported to CMS, 2019-2025
31 companies · $3,015 in 2025
The $3,015 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,616 · 2020: $718 · 2021: $1,832 · 2022: $2,649 · 2023: $1,933 · 2024: $2,364 · 2025: $3,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,293 · Entertainment: $19.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,293.42 |
| Entertainment | $19.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,798.86 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $2,247.42 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $1,608.02 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,437.31 | 2019-2021 | |
| Allergan, INC. | $1,339.44 | 2019-2022 | |
| Abbvie INC. | $906.21 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $657.82 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $628.69 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $623.60 | 2019-2021 | |
| Dompe US, INC. | $565.91 | 2021-2025 | Oxervate |
| Amgen INC. | $346.15 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $342.10 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $341.38 | 2021 | |
| Biotissue Holdings INC. | $198.93 | 2020-2025 | |
| Shire North American Group INC | $196.44 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $113.52 | 2020-2025 | Tearcare System |
| Genzyme Corporation | $113.38 | 2019 | |
| Genentech USA, INC. | $109.42 | 2022 | |
| Eyevance Pharmaceuticals LLC | $103.83 | 2019-2022 | |
| Thea Pharma INC. | $92.27 | 2023-2025 | Iyuzeh |
| Rxsight INC | $69.91 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Glaukos Corporation | $55.24 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Vision Care, INC. | $49.92 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $29.88 | 2021 | |
| Harrow Eye, LLC | $27.53 | 2025 | Vevye |
| Ocular Therapeutix, INC. | $24.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.39 | 2022 | |
| Alcon Research LLC | $22.18 | 2019 | |
| Tearlab Corp | $20.80 | 2021 | |
| Optos, INC. | $19.17 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Apellis Pharmaceuticals, INC. | $14.42 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.